The second batch of centralized mining was launched nationwide, and the ceiling was marked ahead of time to avoid "head breaking" by enterprises

In November, in order to implement the decision-making and deployment of the CPC Central Committee and the State Council on expanding the scope of centralized purchasing and use of drugs organized by the state, in accordance with the notice of the general office of the State Council on printing and distributing the pilot program of centralized purchasing and use of drugs organized by the state (GBF [2019] No In the spirit of regional implementation opinions (medical insurance Fa [2019] No 56), we will comprehensively deepen the reform of centralized drug purchase and use, establish a standardized and normalized mode of centralized drug purchase with volume, and further reduce the burden of drug use on the masses Now we are carrying out the second batch of centralized drug purchase and use organized by the state The new changes in centralized mining focus on "comprehensive deepening", "standardization" and "normalization" and "further reduction" Different from the previous two rounds, this round of centralized procurement document no longer has the word "pilot", but "comprehensive deepening", covering 31 provinces and autonomous regions from a regional perspective, forming a national procurement policy In terms of variety comprehensiveness, it involves 11 treatment fields, including diabetes, tumor, anti infection, cardiovascular, digestive, respiratory, central nervous, analgesia, anti allergy, urinary and liver diseases Different from the previous round, the standardization is reflected in the publication of the most effective application and quotation, the increase of the maximum purchase proportion to 80%, the expansion of the purchase cycle to 3 years, and the increase of the number of shortlisted enterprises to 6 1 Announce the most effective application and quotation and mark in time, and inform the ceiling in advance to avoid vicious competition and promote the sound development of the enterprise In order to avoid no bottom line of enterprise quotation, in order to get involved in intensive mining, the price difference between enterprises was too large in the last round For example, the price of rosuvastatin calcium tablet Haizheng was 0.2 yuan, 33% lower than that of Zhengda Tianqing At the same time, the ceiling price is announced in advance, the transparency of the review is increased, the public's right to know is increased, and a supervision mechanism is formed 2 Increase the maximum purchase proportion to 80% of the unsuccessful enterprises, and reduce the living space In the last round of centralized mining and expansion, the unsuccessful enterprises still have 30% market space Some strong foreign enterprises try their best to expand this market share, and there is still hope for survival This time, only 20% of the market is reserved, which is bound to be a battle of life and death 3 Expand the procurement cycle to the last round of centralized procurement and expansion in 3 years In principle, the procurement cycle is 2 years for the three varieties selected from the enterprises In principle, the procurement cycle is 3 years for 4 or more varieties selected This policy makes the production and operation of enterprises stable and more conducive to the orderly development of centralized mining enterprises 4 Increasing the number of enterprises shortlisted to 6 or 6 means that more enterprises can share the dividend of the national centralized mining policy, so that the "comprehensive deepening" of the centralized mining policy will continue to benefit more enterprises and individuals Avoid some small enterprises supported by a single variety, and suffer heavy losses due to lack of centralized mining However, the large varieties of individual enterprises are not likely to be intensively collected, which will lead to a large scale of layoffs, which will not be conducive to the healthy development of the pharmaceutical market In a sense, this round of centralized mining policy is conducive to the production and operation of enterprises The stable and orderly promotion of policies will promote the healthy development of the pharmaceutical market, and truly achieve "standardization" and "normalization" However, the document points out that "further reduce the burden of drug use for the masses" The most effective application price of acarbose is 264% lower than that of the original research product Digital centralized purchase 1 This round of centralized purchase involves 33 varieties, 50 product specifications, including 17 dual product specifications The invention relates to 5 dosage forms, 1 injection and paclitaxel for injection (albumin binding type) 2 The products involve 23 foreign-funded manufacturers, some of which have no original research products listed in China It involves 11 treatment fields, including 15 anti infection regulations, 11 cardiovascular regulations and 4 diabetes regulations It covers not only the common drugs, but also the rare disease variety bosentan 3 The top five varieties were acarbose, tegio, azithromycin, olmesartan ester and moxifloxacin Pfizer's Zhejiang winning bid price is 19.9, and according to the most effective bidding price of 3.75, the price will be reduced by 431% This is not a precipice price reduction We believe that Pfizer will carefully consider the centralized mining of the company 4 Proportion of common names of related varieties of foreign enterprises Bayer generic varieties involve 40% of the total purchase amount, Japan Dapeng 12% and Pfizer 7% Bayer involves three varieties, acarbose (betanping), moxifloxacin (baifule), and magnesium aluminocarbonate (Daxi) These three products are all big varieties with large share and good brand foundation In the process of transformation, the market will be redefined, and the conventional views of previous research, consistency evaluation and generic drugs will be redefined by policies After the policy, the drugs that have passed the patent period will be divided into national centralized and non centralized varieties In the future, the production, circulation and market share of varieties will be guaranteed When there is no longer any discussion about the feasibility of national centralized mining, it seems that all parties will start to benefit ◆ to further reduce the burden of drug use for patients, the patients finally benefited from surging news reports that Xiaoya was diagnosed with pulmonary hypertension, and "making money" became the life theme of her mother Wang Fang's family In order to earn money, the family is like a top every day, constantly turning The price of a box of alisentan is 3580 yuan, and the cost of a month's combined medication is about 6000 yuan After taking four or five boxes, Wang Fang had to stop anlishengtan Although the doctor asked for it at that time, it couldn't be added "The doctor knew the situation of our patients and looked at the child and shook his head helplessly." Bosentan, a similar product, has been reduced to 69-70 yuan This time, the price reduction of alisentan will provide more treatment options for patients ◆ up to 3 years of payment cycle, to strive for time for the stable growth of enterprises This time, the state collected many policies to help enterprises adapt and turn around It is different from foreign countries that centralized mining has become a national policy The foreign pharmaceutical market is a cliff of patent period, only expired patent drugs will experience price reduction In the context of national centralized purchase, regardless of whether they have been patented or not, price reduction is required to participate in centralized purchase This will become a trend, which also means that under the background of normalization, policies help enterprises to stabilize excessive transformation, and enterprises make use of policy dividend to adjust their weight This payment cycle lasts for up to three years, with stable prices and time for the growth of enterprises ◆ the national centralized procurement will continue to be the pilot achievement of medical reform From December 4 + 7 last year, the national procurement of some urban varieties will be expanded to 25 provinces in September this year, and then the second round of national centralized procurement will be carried out in an all-round way China's centralized procurement model will gradually approach one of the goals of medical reform, "expensive medical treatment" In a real sense, it is different from foreign countries to explore a path of medical reform that conforms to Chinese characteristics In the context of benefits from all parties, we hope that in the cold winter of medicine, enterprises can make good use of policies and adjust their strategies in time When winter comes, will spring be far behind? 37 statement: This article only represents the author and does not represent the position of yaozhi.com You are welcome to communicate and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.